Crestovo has merged with Finch Therapeutics to form Finch Therapeutics Group

Click here to be directed to the Finch Therapeutics Group website. PRISM 3, a clinical trial in recurrent CDI is actively enrolling patients. For more information, please visit clinicaltrials.gov.

LEARN MORE

NEWS

10.23.2017

Finch Therapeutics and Crestovo Announce Merger to Form Finch Therapeutics Group, a Leading, Fully Integrated Microbiome Company

Merged entity includes a diverse pipeline of Full-Spectrum MicrobiotaTM and Rationally-Selected MicrobiotaTM products, an innovative discovery platform, large-scale manufacturing capabilities

FULL ARTICLE

6.27.2017

Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent Clostridium difficile Infection

Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent <em>Clostridium...

FULL ARTICLE

FULL-SPECTRUM MICROBIOTATM

At Crestovo, we are leveraging our industry-leading Full-Spectrum Microbiota™ (FSM™) platform to develop therapeutics that harness the human gut microbiome to restore diversity of healthy microorganisms. Through this approach, we are working to treat conditions with significant unmet medical need where patients are suffering from dysbiosis, including recurrent Clostridium difficile infection (CDI).

VISIT OUR PLATFORM

JOIN OUR TEAM

Crestovo is looking for dynamic, driven individuals to join our team that is focused on treating serious diseases, pioneering breakthroughs in the biopharmaceutical industry and making a positive impact on patients’ lives. Ready to be part of a world-class team at the forefront of the microbiome movement?

CAREER OPPORTUNITIES